# A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

> **NCT03845400** · — · COMPLETED · sponsor: **Shire** · enrollment: 168 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03845400
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-30
- **Primary completion:** 2022-10-22
- **Final completion:** 2022-10-22
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03845400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03845400, "A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03845400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*